The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients
Open accessAbstract
CONTEXT: Solid organ transplant recipients have elevated cancer risk due to immunosuppression and oncogenic viral infections. Because most prior research has concerned kidney recipients, large studies that include recipients of differing organs can inform cancer etiology. OBJECTIVE: To describe the overall pattern of cancer following solid organ transplantation. DESIGN, SETTING, AND PARTICIPANTS: Cohort study using linked data on solid organ transplant recipients from the US Scientific Registry of Transplant Recipients (1987-2008) and 13 state and regional cancer registries. MAIN OUTCOME MEASURES: Standardized incidence ratios (SIRs) and excess absolute risks (EARs) assessing relative and absolute cancer risk in transplant recipients compared with the general population. RESULTS: The registry linkages yielded data on 175,732 solid organ transplants (58.4% for kidney, 21.6% for liver, 10.0% for heart, and 4.0% for lung). The overall cancer risk was elevated with 10,656 cases and an incidence of 1375 per 100,000 person-years (SIR, 2.10 [95% CI, 2.06-2.14]; EAR, 719.3 [95% CI, 693.3-745.6] per 100,000 person-years). Risk was increased for 32 different malignancies, some related to known infections (eg, anal cancer, Kaposi sarcoma) and others unrelated (eg, melanoma, thyroid and lip cancers). The most common malignancies with elevated risk were non-Hodgkin lymphoma (n = 1504; incidence: 194.0 per 100,000 person-years; SIR, 7.54 [95% CI, 7.17-7.93]; EAR, 168.3 [95% CI, 158.6-178.4] per 100,000 person-years) and cancers of the lung (n = 1344; incidence: 173.4 per 100,000 person-years; SIR, 1.97 [95% CI, 1.86-2.08]; EAR, 85.3 [95% CI, 76.2-94.8] per 100,000 person-years), liver (n = 930; incidence: 120.0 per 100,000 person-years; SIR, 11.56 [95% CI, 10.83-12.33]; EAR, 109.6 [95% CI, 102.0-117.6] per 100,000 person-years), and kidney (n = 752; incidence: 97.0 per 100,000 person-years; SIR, 4.65 [95% CI, 4.32-4.99]; EAR, 76.1 [95% CI, 69.3-83.3] per 100,000 person-years). Lung cancer risk was most elevated in lung recipients (SIR, 6.13 [95% CI, 5.18-7.21]) but also increased among other recipients (kidney: SIR, 1.46 [95% CI, 1.34-1.59]; liver: SIR, 1.95 [95% CI, 1.74-2.19]; and heart: SIR, 2.67 [95% CI, 2.40-2.95]). Liver cancer risk was elevated only among liver recipients (SIR, 43.83 [95% CI, 40.90-46.91]), who manifested exceptional risk in the first 6 months (SIR, 508.97 [95% CI, 474.16-545.66]) and a 2-fold excess risk for 10 to 15 years thereafter (SIR, 2.22 [95% CI, 1.57-3.04]). Among kidney recipients, kidney cancer risk was elevated (SIR, 6.66 [95% CI, 6.12-7.23]) and bimodal in onset time. Kidney cancer risk also was increased in liver recipients (SIR, 1.80 [95% CI, 1.40-2.29]) and heart recipients (SIR, 2.90 [95% CI, 2.32-3.59]). CONCLUSION: Compared with the general population, recipients of a kidney, liver, heart, or lung transplant have an increased risk for diverse infection-related and unrelated cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Solid organ transplantation (SOT) recipients have been excluded from clinical trials because of worries concerning alloimmunity, organ rejection, and an increased risk of developing de novo cancer after SOT.154”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,602
A review of human carcinogens—Part B: biological agents
Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., Ghissassi, F. E., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70096-8 · Cited by 2,935
Grulich, A. E., van Leeuwen, M. T., Falster, M. O., & Vajdic, C. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61050-2 · Cited by 2,321
Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.
Breslow, N. E., & Day, N. E. (1987) · PubMed · Cited by 1,684
Welch, H. G., & Black, W. C. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq099 · Cited by 1,627
The design and analysis of cohort studies
Breslow, N. E., & Day, N. E. (1987) · International Agency for Research on Cancer eBooks · Cited by 1,312
The Enigmatic Epidemiology of Nasopharyngeal Carcinoma
Chang, E. T., & Adami, H. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0353 · Cited by 1,297
Cancer Incidence Before and After Kidney Transplantation
Vajdic, C. M., McDonald, S. P., McCredie, M. R. E., van Leeuwen, M. T., Stewart, J. H., Law, M. G., Chapman, J. R., Webster, A. C., Kaldor, J. M., & Grulich, A. E. (2006) · JAMA · doi:10.1001/jama.296.23.2823 · Cited by 1,126
Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report
Opelz, G., & Döhler, B. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00325.x · Cited by 1,080
Cancer after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D. T., & Wang, C. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00450.x · Cited by 1,066
Self-citationCancer risk following organ transplantation: a nationwide cohort study in Sweden
Adami, J., Gäbel, H., Lindelöf, B., Ekström, K., Rydh, B., Glimelius, B. L. G., Ekbom, A., Adami, H., & Granath, F. N. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601219 · Cited by 687
Recommendations for the Outpatient Surveillance of Renal Transplant Recipients
Kasiske, B. L., Vazquez, M. A., Harmon, W., Brown, R. S., Danovitch, G. M., Gaston, R. S., Roth, D., Scandling, J. D., & Singer, G. G. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v11suppl_1s1 · Cited by 627
Self-citationCancer risk after renal transplantation in the nordic countries, 1964–1986
Birkeland, S. A., Storm, H. H., Lamm, L. U., Barlow, L., Blohmé, I., Forsberg, B., Eklund, B. H., Fjeldborg, O. C., FRIEDBERG, M., Frödin, L., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600209 · Cited by 614
Liver Transplantation in the United States, 1999-2008
Thuluvath, P. J., Guidinger, M. K., Fung, J. J., Johnson, L. B., Rayhill, S. C., & Pelletier, S. J. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03037.x · Cited by 574
Collett, D., Mumford, L. L., Banner, N. R., Neuberger, J., & Watson, C. J. E. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03181.x · Cited by 503
Cancer incidence and risk factors after solid organ transplantation
Vajdic, C. M., & van Leeuwen, M. T. (2009) · International Journal of Cancer · doi:10.1002/ijc.24439 · Cited by 476
Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future
de Mattos, A. M., Olyaei, A. J., & Wm, B. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70348-9 · Cited by 429
PRO- AND ANTI-CANCER EFFECTS OF IMMUNOSUPPRESSIVE AGENTS USED IN ORGAN TRANSPLANTATION
Guba, M. O., Graeb, C., Jauch, K., & Geissler, E. K. (2004) · Transplantation · doi:10.1097/01.tp.0000120181.89206.54 · Cited by 361
Cancer Incidence Among Canadian Kidney Transplant Recipients
Villeneuve, P. J., Schaubel, D., Fenton, S., Shepherd, F. A., Jiang, Y., & Mao, Y. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01736.x · Cited by 311
Inflammation in the development of lung cancer: epidemiological evidence
Engels, E. A. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.4.605 · Cited by 295
Self-citationAssignment 1 of the human PHLDA1 gene to chromosome 12q15 by radiation hybrid mapping
Kuske, M., & Johnson, J. P. (2000) · Cytogenetic and Genome Research · doi:10.1159/000015575 · Cited by 288
Identifying the patient at risk for post‐transplant lymphoproliferative disorder
Cockfield, S. M. (2001) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2001.003002070.x · Cited by 274
Post-Transplant Lymphoproliferative Disorders
Dharnidharka, V. R., Webber, S. A., & Green, M. D. (2010) · Springer eBooks · doi:10.1007/978-3-642-01653-0 · Cited by 210
Quinlan, S., Pfeiffer, R., Morton, L. M., & Engels, E. (2011) · American journal of hematology/oncology · doi:10.1002/ajh.21911 · Cited by 198
Self-citationCancer incidence in a kidney-transplanted population
Kyllönen, L., Salmela, K. T., & Pukkala, . (2000) · Transplant International · doi:10.1007/s001470050369 · Cited by 145
van Leeuwen, M. T., Grulich, A. E., Webster, A. C., McCredie, M. R. E., Stewart, J. H., McDonald, S. P., Amin, J., Kaldor, J. M., Chapman, J. R., & Vajdic, C. M. (2009) · Blood · doi:10.1182/blood-2009-02-202507 · Cited by 139
Lymphoproliferative Disease after Renal Transplantation in Australia and New Zealand
Faull, R., HOLLETT, P. R., & McDonald, S. P. (2005) · Transplantation · doi:10.1097/01.tp.0000165098.49658.f3 · Cited by 138
High Frequency of Bronchogenic Carcinoma After Single-lung Transplantation
Dickson, R. P., Davis, R. D., Rea, J. B., & Palmer, S. M. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.09.009 · Cited by 104
Posttransplantation Lymphoproliferative Disorders
Andreoné, P., Gramenzi, A., Lorenzini, S., Biselli, M., Cursaro, C., Pileri, S. A., & Bernardi, M. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.17.1997 · Cited by 93
Heinz‐Peer, G., Schoder, M., Rand, T., Mayer, G. J., & Mostbeck, G. (1995) · Radiology · doi:10.1148/radiology.195.3.7753991 · Cited by 91
Incidence and Risk Factors for Hepatocellular Carcinoma After Solid Organ Transplantation
Hoffmann, C. J., Subramanian, A. K., Cameron, A. M., & Engels, E. A. (2008) · Transplantation · doi:10.1097/tp.0b013e3181837761 · Cited by 67
Self-citationGoh, A., & Vathsala, A. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03303.x · Cited by 63
Bronchogenic Carcinoma after Lung Transplantation: Characteristics and Outcomes
Minai, O. A., Shah, S. S., Mazzone, P. J., Budev, M. M., Sahoo, D. H., Murthy, S. C., Mason, D. P., Pettersson, G., & Mehta, A. C. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818e1259 · Cited by 57
Underestimation of Relative Risks by Standardized Incidence Ratios for AIDS-Related Cancers
Chaturvedi, A. K., Mbulaiteye, S. M., & Engels, E. A. (2008) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.10.005 · Cited by 53
Self-citationAbrahams, N. A., Meziane, M. A., Ramalingam, P., Mehta, A. C., Decamp, M., & Farver, C. F. (2004) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.10.014 · Cited by 48
Risk of Kaposi's sarcoma and of other cancers in Italian renal transplant patients
for the Immunosuppression and Cancer Study Group, Serraino, D., Piselli, P., Angeletti, C., Minetti, E., Pozzetto, A., Civati, G., Bellelli, S., Farchi, F., Citterio, F., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602346 · Cited by 43
Transitional cell carcinoma in renal transplant recipients: the influence of compound analgesics
Swindle, Falk, Rigby, Petrie, Hawley, C. M., & Nicol (1998) · British Journal of Urology · doi:10.1046/j.1464-410x.1998.00496.x · Cited by 41
Kidney and Bladder Cancers Among People With AIDS in the United States
Layman, A. B., & Engels, E. A. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31817ae5da · Cited by 24
Self-citationSingle-lung Transplant Complicated by Unexpected Explant Carcinoma: A Management Dilemma
Ritchie, A. J., Mussa, S., Sivasothy, P. R., & Stewart, S. (2007) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.07.017 · Cited by 16
Flagged first, then by citations
Cited by
Sorted by citations
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
Lucey, M. R., Terrault, N., Ojo, L., Hay, E. J., Neuberger, J., Blumberg, E., & Teperman, L. W. (2013) · Liver Transplantation · doi:10.1002/lt.23566 · Cited by 544
Post-Transplantation Lymphoproliferative Disorders in Adults
Dierickx, D., & Habermann, T. M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1702693 · Cited by 488
Barkholt, L., Flory, E., Jekerle, V., Lucas-Samuel, S., Ahnert, P., Bisset, L., Büscher, D., Fibbe, W. E., Foussat, A., Kwa, M. S. G., et al. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.03.005 · Cited by 420
The Evolving Epidemiology of Nasopharyngeal Carcinoma
Chang, E. T., Ye, W., Zeng, Y.-X., & Adami, H. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-1702 · Cited by 416
Metadata
- Authors
- Engels, E. A., Pfeiffer, R. M., Fraumeni, J. F., Kasiske, B. L., Israni, A. K., Snyder, J. J., Wolfe, R. A., Goodrich, N. P., Bayakly, A. R., Clarke, C. A., Copeland, G., Finch, J. L., Fleissner, M. L., Goodman, M. T., Kahn, A., Koch, L., Lynch, C. F., Madeleine, M. M., Pawlish, K., Rao, C., Williams, M. A., Castenson, D., Curry, M., Parsons, R., Fant, G., & Lin, M.
- Affiliations
- National Institutes of Health (US)
- Arbor Research Collaborative for Health (US)
- Cancer Prevention Institute of California (US)
- Michigan Department of Health and Human Services (US)
- Connecticut Agricultural Experiment Station (US)
- University of Hawaiʻi at Mānoa (US)
- Illinois Department of Public Health (US)
- University of Iowa (US)
- Fred Hutch Cancer Center (US)
- New Jersey Department of Health (US)
- Texas Department of State Health Services (US)
- Information Management Services (US)
- United States Department of Health and Human Services (US)
- Corresponding author
- Engels, Eric A.
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-11-02
- Volume
- 306
- Issue
- 17
- Pages
- 1891
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC3310893
- OpenAlex
- W1964106115
- Cited by
- 1,524
- References
- 43
- Citations by year
- 2026: 83 · 2025: 100 · 2024: 100 · 2023: 89 · 2022: 106 · 2021: 114 · 2020: 134 · 2019: 124 · 2018: 107 · 2017: 114 · 2016: 108 · 2015: 106 · 2014: 97 · 2013: 83 · 2012: 55
- FWCI
- 37.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01pc54405-9-0-0, n01pc35143-20-0-1, n01pc35139-25-0-11, n01pc35142-19-0-0, n01pc35137-18-0-2)
- National Cancer Institute (N01PC35139, HHSN261201000034 C, HHSN261201000036C, HHSN261201000035C, N01‐PC035137, N01 PC035143, N01 PC35142, HHSN261201000037C, N01-PC-54405, HHSN261201000035I, N01-PC-35 137, N01PC-35143, N01 PC035139, HHSN261201000024C, N01 PC035142, N01 PC054405, ZIACP010150)
- National Center for Chronic Disease Prevention and Health Promotion (5U58DP000824-04, 5U58DP000812-03, U58 DP000812, U58 DP000817, U58 DP000805, U58 DP000807, U58 DP000848-04, U58 DP000832, 5U58DP000817-05, U58 DP000824, U58/DP000808, #1U58DP000807-01, 5658DP 000805-04, U58 DP000848, 5U58/DP000808-03)
- Topics
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Keywords
- solid organ transplant recipients, cancer risk, immunosuppression, non-Hodgkin lymphoma, lung cancer, Kaposi's sarcoma, anal cancer, melanoma, thyroid cancer, lip cancer, hepatitis C, cytomegalovirus, Epstein-Barr virus, post-transplant lymphoproliferative disorder
- MeSH terms
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Immune Tolerance, Infant, Male, Middle Aged, Neoplasms, Registries, Risk, United States, Cohort Studies, Incidence, Organ Transplantation, Immunocompromised Host, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
